Session Details
JSNM Oral 3:Drug discovery and development 1
Thu. Nov 13, 2025 3:50 PM - 5:00 PM JST
Thu. Nov 13, 2025 6:50 AM - 8:00 AM UTC
Thu. Nov 13, 2025 6:50 AM - 8:00 AM UTC
Room 2（1F, Exhibition Hall 2 A, Kyoto International Exhibition Hall 'Miyako Messe'）
座長：小川 数馬（金沢大学医薬保健学域薬学系 臨床分析科学研究室）、志賀 哲（福島県立医科大学 先端臨床研究センター）
[1-MO3-1]Preclinical radio-theranostic feasibility of64Cu-/225Ac-PD-32766 peptide for ccRCC
Shota Tsuchida1、Yoshihide Mizukoshi1、Shintaro Kato1、Hiroko Inaba1、Tatsuro Kotake1、Takanori Aoki1、Yuichi Funase2、Kentaro Suzuki2、Hidetomo Kitamura1、Satoshi Matsushima2、Masato Murakami1,2 (1.ペプチドリーム、2.PDRファーマ)
[1-MO3-2]演題取下げ
[1-MO3-3]Development of in vivo stable astatobenzoate conjugate peptides
Tomoya Uehara1、Mutsuho Murata2、Sohta Tatsuta2、Kento Kannaka1、Hiroyuki Suzuki1、Kazuhiro Takahashi3 (1.Chiba University Graduate School of Pharmaceutical Sciences, Chiba, Japan、2.Department of Pharmacy, Chiba University, Chiba, Japan、3.Fukushima Medical University, Fukushima, Japan)
[1-MO3-4]Drug kinetics and effect of local administration of astatine-labeled gold nanoparticles
Hiroki Kato1、Hiroaki Shimamoto2、Yuichiro Kadonaga1、Kazuhiro Ooe1、Seiichi Yamamoto3、Xuhao Huang5、Atsushi Shimoyama4、Kazuya Kabayama1、Atsushi Toyoshima1、Shumei Murakami2、Koichi Fukase1 (1.Department of Advanced Radioisotope Medicine, Institute for Radiation Sciences, The University of Osaka, Suita, Japan、2.School & Graduate School of Dentistry The University of Osaka, Suita, Japan、3.Waseda Research Institute for Science and Engineering, Tokyo, Japan、4.Department of Chemistry, Osaka University Graduate School of Science, Toyonaka, Japan、5.Immunology Frontier Research Center (IFReC), The University of Osaka, Suita, Japan)
[1-MO3-5]Biodistribution of PEG-modified astatine-labelled gold nanoparticles
Hiroki Kato1、Yuichiro Kadonaga1、Kazuhiro Ooe1、Xuhao Huang3、Atsushi Shimoyama2、Kazuya Kabayama1、Atsudhi Toyoshima1、Koichi Fukase1 (1.Department of Advanced Radioisotope Medicine, Institute for Radiation Sciences, The University of Osaka, Suita, Japan、2.Department of Chemistry, Osaka University Graduate School of Science、3.IFReC)
[1-MO3-6]Reactivity of S-Arylphenothiazinium salts with Nucleophiles
Masayuki Fujinaga1、Masanao Ogawa1,2、Yusuke Kurihara1,2、Nobuki Nengaki1,2、Wakana Mori1、Katsushi Kumata1、Ming-Rong Zhang1 (1.Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan、2.SHI Accelerator Service Ltd, Tokyo, Japan)
[1-MO3-7]Fundamental study on a targeted alpha therapeutic agent for Alzheimer's disease
Rikuto Kashiyama1、Hiroyuki Watanabe1、Takahiro Akasaka1、Hiroyuki Fujimoto2、Masashi Murakami3、Kazuhiro Ooe3、Atsushi Toyoshima3、Kazuma Nakashima1、Masahiro Ono1 (1.Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan、2.Agency for Health, Safety and Environment, Kyoto University, Kyoto, Japan、3.Institute for Radiation Sciences, Osaka University, Osaka, Japan)